Абстракт

Objectives: The authors aimed to analyze the satisfaction index of 97 patients submitted to the Phenol-croton peel procedure, in order to ascertain short- or long-term side effects, and satisfaction following the procedure. Introduction: Phenol-croton peels are indicated for skin rejuvenation, a highly desired effect in the dermatological field. This procedure improves the appearance and texture of the skin by stimulating cell regeneration and reshaping. Phenol-croton peel is expected to promote excellent results in a relatively short time, with the potential to improve not only the appearance and lagginess, but also the patient's quality of life. However, studies published in recent years use relatively small samples, ranging from 9 to 16 patients. Materials / method: We retrospectively reviewed 97 patients, with phototypes I-III, who underwent phenol-croton peel from 2015-2022. The study was approved by the Ethics Committee of Hospital Mário Pena and Plataforma Brasil. Data collection involved 97 participants who gave their written consent to the study and responded to the interview. Their responses were organized into groups according to the area where the peeling was performed (full face versus localized peel) and years of evolution after the procedure. The data were statistically analyzed, considering satisfaction and adverse events. Results: On a scale of 1 to 5, 91.8% (n=89) of participants rated the procedure with a score higher than 4, with 69% (n=67) of them giving the highest score. Regarding adverse effects, only 12.4% (n=12) of the sample members reported these occurrences. In addition, there was a tendency towards a reduction of approximately 30% (5/17) in side effects after three months (p = 0.062), considering all treatments. Conclusion: The majority of patients interviewed were satisfied with the procedure. Phenol croton peel, despite prolonged recovery time, leads to a high degree of satisfaction when well indicated among patients with phototype 1-3, with a 17,5% incidence of recent and 12,4% of late complications.